Therapeutic Approach

Archive: May, 2019

Ritter Pharmaceuticals Shares Data from New Study Illuminating the Life Challenges of a Lactose Intolerance Sufferer

Ritter Pharmaceuticals Shares Data from New Study Illuminating the Life Challenges of a Lactose Intolerance Sufferer Current treatment options only provide full symptom relief to 9% of patients; 90% of sufferers want a better solution LOS ANGELES (May 30, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative […]

Leave Your Comments »

Ritter Pharmaceuticals Shares New Market Research Illuminating the Life Challenges of a Lactose Intolerance Sufferer

Ritter Pharmaceuticals Shares New Market Research Illuminating the Life Challenges of a Lactose Intolerance Sufferer Current treatment options only provide full symptom relief to 9% of patients; 90% of sufferers want a better solution LOS ANGELES (May 30, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2019

LOS ANGELES (May, 14 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (“LI”), today reported […]

Leave Your Comments »

Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

Top-line Data Readout on Target for early Q4 2019 LOS ANGELES (May 7, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that the final patient in its first pivotal Phase 3 clinical trial of RP-G28 […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD